EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HRCT-assessed fibrosis burden predicts mortality better than pulmonary function decline in progressive pulmonary fibrosis

Nilüfer Yiğit, Göksel Altınışık, Hüseyin Gökhan Yavaş, Hande Şenol, Furkan Ufuk

Eurasian Journal of Pulmonology · 2026

DOI: 10.14744/ejp.2026.89103 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND AND AIM: Progressive pulmonary fibrosis (PPF) is a clinically significant phenotype observed across fibrotic interstitial lung diseases (ILDs), characterized by pulmonary functional decline, radiologic progression, and worsening symptoms. While declines in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) are widely used to define progression, the prognostic value of baseline radiologic fibrosis burden in real-world PPF cohorts remains incompletely defined. We aimed to evaluate the relationships among HRCT-derived fibrosis extent, pulmonary function decline, and overall survival in patients with PPF. METHODS: In this retrospective single-center study, 99 patients with progressive fibrotic ILD who were followed between 2010 and 2019 were included. PPF was defined according to accepted criteria, including functional, radiologic, and symptomatic progression. The extent of fibrosis on HRCT was assessed by two independent radiologists using a semi-quantitative visual scoring method. Cox regression models were used to identify predictors of mortality. RESULTS: Baseline HRCT fibrosis extent was independently associated with mortality. In a multivariable analysis adjusted for age, sex, smoking status, and diagnosis, each 1% increase in fibrotic involvement was associated with a 5% higher risk of death (HR 1.050, 95% CI 1.025–1.076; p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →